<DOC>
	<DOCNO>NCT00603265</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness ADL5859 relieve pain associate diabetic peripheral neuropathy ( DPN ) compare placebo duloxetine ( marketed drug approve treatment painful DPN ) . The pain symptom DPN think due damage nerve cause diabetes .</brief_summary>
	<brief_title>Safety Efficacy Study ADL5859 Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>Participants permit take acetaminophen 650 975 mg every 4 6 hour ( total 4 gram 24 hour ) need pain relief .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Male female participant 18 75 year age , inclusive Body weight least 45 kilogram ( kg ) Diabetes mellitus ( type I II ) document stable glycemic control period least 3 month , indicate glycosylated hemoglobin ( HbgAIC ) less equal 12 % stable dose insulin oral diabetic medication 90 day prior start study medication No change diabetic medication plan duration study Evidence symmetrical , bilateral pain low extremity due diabetic peripheral neuropathy ( DPN ) Presence daily pain due DPN least 3 month Score great equal 3 physical examination portion Michigan Neuropathy Screening Instrument ( MNSI ) Average weekly pain score great equal 4 numeric pain rating scale ( NPRS ) symmetrical neuropathic pain foot leg For male participant , surgically sterile agree use appropriate method contraception For female participant childbearing potential , surgically sterile use intrauterine device , injectable , transdermal , combination oral contraceptive deem highly effective Food Drug Administration ( FDA ) Be willing able comply protocol requirement Be able understand willing provide write informed consent English Presence pain condition distinguish DPN Presence significant renal disease , indicate serum creatinine great equal 2.0 milligram per deciliter ( mg/dL ) , presence significant hepatic disease Have history seizure disorder Presence serious unstable cardiovascular disease , respiratory disease , hematologic illness , psychiatric condition History evidence symptomatic orthostatic hypotension History major depressive disorder , generalize anxiety disorder , eat disorder , substance abuse ( include alcohol ) within past year History evidence mania , bipolar disorder , psychosis History allergy acetaminophen duloxetine Score great equal 18 Beck Depression Inventory II ( BDIII ) score great zero Item 9 BDIII Use follow concomitant medication : fluvoxamine ; quinolone antimicrobial ( ciprofloxacin enoxacin ) ; selective serotonin reuptake inhibitor ( SSRIs ) ; serotonin norepinephrine reuptake inhibitor ( SNRIs ) ; tricyclic antidepressant ; opioids ; nonsteroidal antiinflammatory drug ( NSAIDS ) ; anticonvulsant ; aspirin ( exception lowdose aspirin cardiovascular prophylaxis ) ; cytochrome P4503A ( CYP3A ) Pglycoprotein transporter inhibitor Pregnant , lactate , plan become pregnant study Presence foot toe amputation Participation another study investigational compound within previous 30 day prior study medication administration , concurrent participation another clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Diabetic Peripheral Neuropathy</keyword>
	<keyword>Neuropathic Pain</keyword>
</DOC>